HALOZYME THERAPEUTICS, INC. (HALO): debt financing — Halozyme issues $1.5B in convertible notes; repurchases $1.02B of existing notes

HALOZYME THERAPEUTICS, INC.

Issued $750M 0% convertible notes due 2031 and $750M 0.875% notes due 2032; net proceeds ~$1.47B.
Used ~$1.02B to repurchase 0.25% notes due 2027 and 1.00% notes due 2028 via private transactions.
Entered capped call transactions ($182.7M) to limit dilution; cap price $136.78 vs conversion price $87.20.
Remaining proceeds for general corporate purposes, potential acquisitions, and future note repurchases.

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 1.0

HALOZYME THERAPEUTICS, INC. incurred convertible notes of $1,500.0 million aggregate principal amount with The Bank of New York Mellon Trust Company, N.A. at 0% maturing due 2031.

Instrument: convertible notes
Principal: $1,500.0 million aggregate principal amount
Counterparty: The Bank of New York Mellon Trust Company, N.A.
Rate: 0%
Maturity: due 2031
Event: incurrence

Exact text from the filing

completed its previously announced sale of $1,500.0 million aggregate principal amount convertible senior notes, consisting of (i) $750.0 million of 0% Convertible Senior Notes due 2031

View on SEC.gov

Debt Financings SEC 8-K Item 2.03/2.04 confidence 1.0

HALOZYME THERAPEUTICS, INC. incurred convertible notes of $750.0 million in aggregate principal amount with The Bank of New York Mellon Trust Company, N.A. at 0.875% maturing due 2032.

Instrument: convertible notes
Principal: $750.0 million in aggregate principal amount
Counterparty: The Bank of New York Mellon Trust Company, N.A.
Rate: 0.875%
Maturity: due 2032
Event: incurrence

Exact text from the filing

(ii) $750.0 million in aggregate principal amount of 0.875% Convertible Senior Notes due 2032

View on SEC.gov

Equity Issuances SEC 8-K Item 3.02/3.03 confidence 0.9

HALOZYME THERAPEUTICS, INC. issued $1,500.0 million aggregate principal amount of convertible senior notes, consisting of $750.0 million of 0% Convertible Senior Notes due 2031 and $750.0 million of convertible note to initial purchasers (subsequently resold to qualified institutional buyers) for net proceeds of approximately $1.47 billion after deducting discounts, commissions, and offering expenses.

Security: convertible note
Shares: $1,500.0 million aggregate principal amount of convertible senior notes, consisting of $750.0 million of 0% Convertible Senior Notes due 2031 and $750.0 million
Purchaser: initial purchasers (subsequently resold to qualified institutional buyers)
Consideration: net proceeds of approximately $1.47 billion after deducting discounts, commissions, and offering expenses

Exact text from the filing

from registration requirements, or in a transaction not subject to, such registration requirements. The Company received net proceeds from the offering of approximately $1.47 billion after deducting the Initial Purchasers’ discounts and commissions and the Company’s estimated offering expenses. The Company used approximately $182.7 million of the net proceeds

View on SEC.gov

10 debt financings filed in the last 30 days. Browse all debt financings →

HALOZYME THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001193125-25-277988

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.